Malaria Infection Diagnosed by Polymerase Chain Reaction (PCR) as a Means of Evaluating Pre-Erythrocytic Candidate Malaria Vaccines

Inclusion Criteria:

• Healthy volunteers aged 15-45 years
• Signed informed consent form

Exclusion Criteria:

• Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy, immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease or neurological illness.
• Any clinical evidence of immunosuppression such as oral candida, stomatitis, aphthous or septic ulceration, septic skin lesions or any clinical or laboratory evidence of infection or immunosuppression.
• History of splenectomy
• Haematocrit of less than 30%
• Serum creatinine concentration >130mmol/L
• Serum ALT concentration >80 IU/L
• Blood transfusion within one month of the beginning of the study
• History of vaccination with a previous experimental malaria vaccine
• Administration of any other vaccine or immunoglobulin within two weeks of scheduled vaccination.
• Positive HIV antibody test.
• Positive colorimetric test for G-6-P-D deficiency.
• Current participation in another clinical trial, or within 12 weeks of this study.
• Lack of parental consent if volunteer is aged under 18
• Likelihood of travel away from the study area for the duration of the study
• Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial
• Known allergy to sulfadoxine/pyrimethamine (SP), Artesunate or Lapdap
• Drug or alcohol addiction
• Egg allergy